Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.

Pressey JG, Adams J, Harkins L, Kelly D, You Z, Lamb LS Jr.

Medicine (Baltimore). 2016 Sep;95(39):e4909. doi: 10.1097/MD.0000000000004909.

2.

Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.

Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y, Kojima S, Kuzushima K.

J Immunother. 2012 Oct;35(8):598-606.

PMID:
22996365
3.

Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.

Di Carlo E, Bocca P, Emionite L, Cilli M, Cipollone G, Morandi F, Raffaghello L, Pistoia V, Prigione I.

Mol Ther. 2013 May;21(5):1034-43. doi: 10.1038/mt.2013.38. Epub 2013 Mar 12.

4.

Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP.

Blood. 2003 Jul 1;102(1):200-6. Epub 2003 Mar 6.

PMID:
12623838
5.

Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.

Nagamine I, Yamaguchi Y, Ohara M, Ikeda T, Okada M.

Hiroshima J Med Sci. 2009 Mar;58(1):37-44.

PMID:
19400555
6.

Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.

Poccia F, Gioia C, Martini F, Sacchi A, Piacentini P, Tempestilli M, Agrati C, Amendola A, Abdeddaim A, Vlassi C, Malkovsky M, D'Offizi G.

AIDS. 2009 Mar 13;23(5):555-65. doi: 10.1097/QAD.0b013e3283244619.

PMID:
19238075
7.

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri S, D'Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC.

Cancer Res. 2007 Aug 1;67(15):7450-7.

8.

Expansion of human peripheral blood γδ T cells using zoledronate.

Kondo M, Izumi T, Fujieda N, Kondo A, Morishita T, Matsushita H, Kakimi K.

J Vis Exp. 2011 Sep 9;(55). pii: 3182. doi: 10.3791/3182.

9.

Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.

Noguchi A, Kaneko T, Kamigaki T, Fujimoto K, Ozawa M, Saito M, Ariyoshi N, Goto S.

Cytotherapy. 2011 Jan;13(1):92-7. doi: 10.3109/14653249.2010.515581. Epub 2010 Sep 10.

PMID:
20831354
10.

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.

Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K.

Cancer Immunol Immunother. 2011 Aug;60(8):1075-84. doi: 10.1007/s00262-011-1021-7. Epub 2011 Apr 26.

PMID:
21519826
11.

Hepatocellular carcinoma cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate.

Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T.

Int J Oncol. 2016 May;48(5):1794-804. doi: 10.3892/ijo.2016.3403. Epub 2016 Feb 19.

12.

Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.

Poonia B, Pauza CD.

Cytotherapy. 2012 Feb;14(2):173-81. doi: 10.3109/14653249.2011.623693. Epub 2011 Oct 27.

PMID:
22029653
13.

Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2.

Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, Nakamura H, Yamanishi H, Terada N, Okamura H.

J Immunother. 2010 Apr;33(3):287-96. doi: 10.1097/CJI.0b013e3181c80ffa.

PMID:
20445349
14.

Impaired function of gamma-delta lymphocytes in melanoma patients.

Petrini I, Pacini S, Galimberti S, Taddei MR, Romanini A, Petrini M.

Eur J Clin Invest. 2011 Nov;41(11):1186-94. doi: 10.1111/j.1365-2362.2011.02524.x. Epub 2011 Apr 1.

PMID:
22775565
15.

Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.

Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Takamoto S, Matsushita H, Kakimi K.

J Immunother. 2011 Mar;34(2):202-11. doi: 10.1097/CJI.0b013e318207ecfb.

PMID:
21304399
16.

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.

Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, La Mendola C, Guggino G, D'Asaro M, Orlando V, Scarpa F, Roberts A, Caccamo N, Stassi G, Dieli F, Hayday AC.

Clin Exp Immunol. 2010 Aug;161(2):290-7. doi: 10.1111/j.1365-2249.2010.04167.x. Epub 2010 May 10.

17.
18.

[Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma].

Li Z, Tang J, Sun L, Ye Z.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Jan;29(1):6-9. Chinese.

PMID:
23294710
19.

In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.

Burjanadzé M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, Romagne F, Morel Y, Rossi JF, Klein B, Lu ZY.

Br J Haematol. 2007 Oct;139(2):206-16.

PMID:
17897296
20.

[Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate].

Li ZX, Sun LL, Cheng RL, Sun ZW, Ye ZM.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Aug;28(8):822-4. Chinese.

PMID:
22863589

Supplemental Content

Support Center